Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex differences in hospitalized adult patients with cellulitis: A prospective, multicenter study.
Collazos J, de la Fuente B, de la Fuente J, García A, Gómez H, Rivas-Carmenado M, Suárez-Zarracina T, García-Carús E, Suárez-Diaz S, Enríquez H, Sánchez P, Alonso M, López-Cruz I, Martín-Regidor M, Martínez-Alonso A, Guerra J, Artero A, Blanes M, Asensi V. Collazos J, et al. Among authors: de la fuente b, de la fuente j. Int J Infect Dis. 2021 Mar;104:584-591. doi: 10.1016/j.ijid.2021.01.044. Epub 2021 Jan 27. Int J Infect Dis. 2021. PMID: 33508477 Free article.
IL-1 alpha (-889) promoter polymorphism is a risk factor for osteomyelitis.
Asensi V, Alvarez V, Valle E, Meana A, Fierer J, Coto E, Carton JA, Maradona JA, Paz J, Dieguez MA, de la Fuente B, Moreno A, Rubio S, Tuya MJ, Sarasúa J, Llames S, Arribas JM. Asensi V, et al. Among authors: de la fuente b. Am J Med Genet A. 2003 Jun 1;119A(2):132-6. doi: 10.1002/ajmg.a.20137. Am J Med Genet A. 2003. PMID: 12749050
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.
Cellulitis in adult patients: A large, multicenter, observational, prospective study of 606 episodes and analysis of the factors related to the response to treatment.
Collazos J, de la Fuente B, García A, Gómez H, Menéndez C, Enríquez H, Sánchez P, Alonso M, López-Cruz I, Martín-Regidor M, Martínez-Alonso A, Guerra J, Artero A, Blanes M, de la Fuente J, Asensi V. Collazos J, et al. Among authors: de la fuente b, de la fuente j. PLoS One. 2018 Sep 27;13(9):e0204036. doi: 10.1371/journal.pone.0204036. eCollection 2018. PLoS One. 2018. PMID: 30260969 Free PMC article.
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Román A, Santos I, Giner L, Armiñanzas C, Montero M, Manzardo C, Cifuentes C, García C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodríguez C, Gaspar G, Pérez L, Losa JE, Force L, Veloso S, Martínez-Alfaro E, Jarrín I, De Miguel M, González Garcia J; GeSIDA 8514 Study Group. Fanciulli C, et al. Among authors: de la fuente b. HIV Med. 2022 Aug;23(7):705-716. doi: 10.1111/hiv.13229. Epub 2022 Jan 17. HIV Med. 2022. PMID: 35037379 Free PMC article.
No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients.
Collazos J, Pérez-Is L, de la Fuente B, Morano L, Rivas-Carmenado M, Rodriguez M, Romero-Favela A, de Jesús Fonseca-González G, Melón S, Diaz-Arias J, Valle-Garay E, Asensi V. Collazos J, et al. Among authors: de la fuente b. Sci Rep. 2024 Mar 29;14(1):7534. doi: 10.1038/s41598-024-57845-x. Sci Rep. 2024. PMID: 38553507 Free PMC article.
126 results